Pharma BD Deal Intelligence
Quanterix and Akoya Biosciences announced a definitive merger agreement on January 10, 2025 under which Quanterix will acquire Akoya in an all-stock transaction, with Akoya shareholders receiving 0.318 Quanterix shares per Akoya share. The combination was positioned as the first integrated solution for ultra-sensitive detection of blood- and tissue-based protein biomarkers, with approximately $40 million in expected annual cost synergies by end-2026. Quanterix shareholders would own approximately 70% of the combined company. Deal value left NULL: the announcement disclosed an exchange ratio rather than a fixed dollar consideration. Terms were subsequently amended in April 2025.
← Browse all deals · How we score deals
More: 2025 deals